Background Data are needed to inform the positioning of biologic therapy in the treatment of
moderate-to-severe Crohn's disease, both first line and after previous biologic exposure. We …

Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Background Active-comparator trials are important to inform patient and physician choice.
We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or …

Crohn's disease [CD] is a chronic inflammatory bowel disease [IBD] that can result in
progressive bowel damage and disability. 1 CD can affect individuals of any age, from …

Abstract Background and Aims: The efficacy of azathioprine for Crohn's disease under
adalimumab treatment remains obscure. Methods: In an open-labelled prospective study …

Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory
bowel disease (IBD). We conducted a comprehensive review of meta-analyses to …

Im Jahr 2019 wurden etwa 25 500 Patient* innen mit M. Crohn im Krankenhaus stationär
behandelt [1]. Meistens tritt die Erkrankung in der Adoleszenz und im jungen …

Background To review the frequency with which anti-TNF-α loses its effect and dose
“intensification” is required for Crohn's disease (CD) treatment. Methods Electronic …

Inflammation has been shown to play an important role in the mechanisms involved in the
pathogenesis of hypertension. Accordingly, innate and adaptive immune responses …

Background Vedolizumab [VDZ] is an anti-integrin monoclonal antibody effective in
ulcerative colitis [UC] and Crohn's disease [CD]. Several real-world experience [RWE] …